Axial Spondyloarthritis (axSpA) Market Report 2026

The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $6.56 billion in 2025 to $7.09 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing awareness of inflammatory spinal disorders, expanded use of TNF inhibitors, improved diagnostic imaging availability, growth in rheumatology specialty care, increased treatment adherence initiatives.

The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing adoption of JAK inhibitors and IL therapies, rising investments in personalized medicine, expansion of early screening programs, growing use of digital disease monitoring platforms, continued innovation in biologic drug development. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted anti-inflammatory drugs, growing focus on early diagnosis and disease monitoring, expansion of personalized treatment approaches, enhanced integration of digital health tools.

The growing aging population is anticipated to drive the expansion of the axial spondyloarthritis (axSpA) market in the coming years. An aging population refers to a demographic shift marked by a rising share or higher proportion of elderly individuals within the overall population. Managing and treating axSpA in older adults offers several advantages, including enhanced joint function and mobility, better quality of life, prevention of spinal structural damage, lower healthcare costs, reduced risk of disability, and more effective treatment approaches. For example, in 2023, Age UK, a UK-registered charity, reported that England had 11 million people aged over 65. This number is expected to rise by 10% over the next five years and by 32% by 2043, representing increases of approximately 1.1 million and 3.5 million people, respectively. The population aged 85 and above, which is the group most likely to require health and care services, is also forecast to grow significantly, increasing by 8.2% in the next five years and by 62.7% by 2043, equivalent to around 126,000 and 956,000 people, respectively. As a result, the expanding aging population is contributing to the growth of the axial spondyloarthritis (axSpA) market.

Major companies in the axial spondyloarthritis (axSpA) market are focusing on developing innovative treatments, such as next-generation biologic therapies, to meet the increasing demand for effective options that reduce inflammation and improve long-term disease control. These biologic drugs target specific immune pathways, offering a more precise approach than conventional anti-inflammatory medications, which mainly manage symptoms without addressing the underlying immune causes. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the European Commission for the marketing authorization of BIMZELX (bimekizumab) to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation, such as elevated C-reactive protein, with these European Union (EU) approvals representing the drug’s first global marketing authorizations for axial spondyloarthritis.

In July 2024, Spine BioPharma, a US-based biopharmaceutical company, entered into a partnership with Ensol BioSciences to advance the development of SB-01 for fibrotic disorders, including axial spondyloarthritis (axSpA). Through this collaboration, the companies seek to broaden SB-01’s therapeutic application to fibrosis-related musculoskeletal conditions, support its clinical development, and accelerate pathways toward commercialization for axSpA and related indications. Ensol BioSciences is a South Korea-based biotechnology company focused on protein-based drug discovery and development.

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the axial spondyloarthritis (axspa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the axial spondyloarthritis market by increasing costs of imported biologic drugs, pharmaceutical raw materials, injectable delivery systems, and diagnostic imaging equipment. North America and Europe are most affected due to dependence on cross-border biologics manufacturing and distribution, while Asia-Pacific faces cost pressures on active ingredient imports. These tariffs are contributing to higher therapy prices and reimbursement challenges. At the same time, they are supporting local biologics manufacturing, regional supply chain diversification, and increased investments in domestic pharmaceutical production capabilities.

The axial spondyloarthritis (axspa) market research report is one of a series of new reports that provides axial spondyloarthritis (axspa) market statistics, including axial spondyloarthritis (axspa) industry global market size, regional shares, competitors with a axial spondyloarthritis (axspa) market share, detailed axial spondyloarthritis (axspa) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axspa) industry. This axial spondyloarthritis (axspa) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Axial spondyloarthritis (axSpA) is a long-term inflammatory disorder that primarily affects the axial skeleton, including the spine and sacroiliac joints. It is marked by inflammation of the sacroiliac joints, leading to ongoing back pain and stiffness.

The primary forms of axial spondyloarthritis (axSpA) include ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing spondylitis (AS) is a type of arthritis that affects the ligaments and joints of the spine, where over-the-counter anti-inflammatory drugs such as naproxen and ibuprofen are widely used to reduce pain, inflammation, and muscle stiffness, helping to delay complications and spinal deformities. The range of available therapies includes anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy, offered in various dosage forms such as tablets and injections for multiple treatment categories including tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These treatments are distributed through different end-user channels such as hospital pharmacies, retail pharmacies, and online pharmacy stores.

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.